Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 Cipla Q3 Net Profit Soars 49% to Rs 1,571 Crore Cipla's net profit surged 49% to Rs 1,571 crore in Q3 FY25, driven by strong revenue ...

Do you ever ask yourself why some company logos we see at events get stuck in our heads while others vanish quicker than invisible ink? It’s not magic, and it isn’t luck either. The truth is that they ...

The Quarterly Results page of Cipla Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.

Stocks To Buy Today: Intraday BUY/SELL Calls By Sumeet Bagadia On Tuesday, 18th Feb Stock Market Crashed On February 17: Why Sensex Dropped 645 Pts & Nifty Fell 204 Pts On Monday? Stock Market ...

The Capital Structure page of Cipla Ltd. presents the Authorized Capital, Issued Capital, and Paid-Up Equity Capital of the company over the period.

Stock Market Crashed On February 17: Why Sensex Dropped 645 Pts & Nifty Fell 204 Pts On Monday? Stock Market Live Updates: Nifty 50 Hovers Around 22,800, Sensex Dips 300 Pts; Nifty Bank Down 0.50% ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Revenue 25,774.09 22,753.12 21,763.34 19,159.59 ...

The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...